Illumina, Inc. (NASDAQ:ILMN) Short Interest Up 28.6% in January

Illumina, Inc. (NASDAQ:ILMN) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 8,300,465 shares, a growth of 28.6% from the January 15th total of 6,455,325 shares. Based on an average daily trading volume, of 2,093,599 shares, the short-interest ratio is currently 4.0 days. Currently, 5.4% of the shares of the stock are short sold. Currently, 5.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,093,599 shares, the short-interest ratio is currently 4.0 days.

Insider Activity at Illumina

In other news, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Illumina

A number of hedge funds have recently made changes to their positions in ILMN. Elyxium Wealth LLC purchased a new stake in shares of Illumina during the fourth quarter worth approximately $25,000. Board of the Pension Protection Fund purchased a new position in shares of Illumina in the fourth quarter worth about $26,000. Creative Capital Management Investments LLC boosted its position in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in Illumina during the fourth quarter worth approximately $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN traded up $2.37 on Monday, reaching $116.81. 1,902,859 shares of the company’s stock traded hands, compared to its average volume of 2,330,076. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The firm has a market cap of $17.86 billion, a price-to-earnings ratio of 21.43, a P/E/G ratio of 2.23 and a beta of 1.45. The stock has a 50 day moving average price of $137.29 and a 200-day moving average price of $116.64.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.Illumina’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts predict that Illumina will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Barclays boosted their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Finally, Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $129.17.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.